Foundation Fighting Blindness Retinal Degeneration Fund 13D and 13G filings for Opus Genetics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-11 8:52 pm Sale | 2025-12-09 | 13D | Opus Genetics, Inc. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 5,492,171 8.000% | -4,000,000 (-42.14%) | Filing |
| 2025-05-06 5:55 pm Purchase | 2025-04-30 | 13D | Opus Genetics, Inc. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 9,492,171 15.900% | 6,927,419 (+270.10%) | Filing |
| 2024-10-29 5:26 pm Purchase | 2024-10-22 | 13D | Opus Genetics, Inc. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 2,564,752 8.160% | 2,564,752 (New Position) | Filing |